| 张丽娟,韩 娜,丁亚文,张金玲,冯 刚.艾迪注射液联合吉非替尼片治疗EGFR阳性晚期非小细胞肺癌的临床疗效观察[J].,2018,(14):2696-2700 |
| 艾迪注射液联合吉非替尼片治疗EGFR阳性晚期非小细胞肺癌的临床疗效观察 |
| Clinical Observation of Gefitinib Tablets Combined with Addie Injection in the Treatment of Advanced Non-Small Cell Lung Cancer with EGFR Positive |
| 投稿时间：2017-10-28 修订日期：2017-11-23 |
| DOI：10.13241/j.cnki.pmb.2018.14.020 |
| 中文关键词: 吉非替尼片 艾迪注射液 EGFR 晚期 非小细胞肺癌 疗效 预后 |
| 英文关键词: Gefitinib tablets Addie injection EGFR Advanced Non-small cell lung cancer Curative effect Prognosis |
| 基金项目: |
|
| 摘要点击次数: 501 |
| 全文下载次数: 284 |
| 中文摘要: |
| 摘要 目的：探讨艾迪注射液结合吉非替尼片治疗表皮生长因子受体（EGFR）阳性晚期非小细胞肺癌（NSCLC）的临床疗效。方法：选取2012年1月至2015年12月在航天中心医院和华中科技大学同济医学院附属普爱医院治疗的EGFR阳性晚期NSCLC患者62例，按照随机双盲法分为实验组和对照组各31例，实验组给予艾迪注射液联合吉非替尼片治疗，对照组单纯使用吉非替尼片治疗，两组均治疗2个疗程。比较两组患者的治疗效果及其不良反应的发生情况，随访1年，比较两组患者的存活率。结果：实验组有效率和疾病控制率高于对照组（P<0.05），实验组疼痛减轻率、睡眠质量改善率和饮食改善率较对照组升高（P<0.05），实验组不良反应的发生率稍低于对照组，但是差异无统计学意义（P>0.05）。随访1年发现实验组28例存活，对照组22例存活，实验组的存活率高于对照组（P<0.05）。结论：艾迪注射液联合吉非替尼片较单纯应用吉非替尼片治疗EGFR阳性晚期NSCLC的疗效更好，能够改善患者睡眠质量和饮食状况，减轻疼痛，用药安全性较好，从而改善患者的预后，值得临床推广。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the clinical efficacy of Gefitinib tablets combined with Addie injection in the treatment of ad- vanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) positive. Methods: 62 cases of advanced NSCLC with EGFR positive patients treated in Aerospace Central Hospital and Puai Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology from January 2012 to December 2015 were selected. They were divided into experi- mental group (n=31) and control group (n=31) according to the randomized double blind method. The experimental group were treated with Addie injection combined with Gefitinib Tablets, and the control group were only treated with Gefitinib Tablets, the two groups were treated for 2 courses. The treatment effect and adverse reactions of the two groups were compared. Followed up for 1 year, the survival rate of the two groups was compared. Results: The effective rate and disease control rate in the experimental group were higher than those in the control group (P<0.05). The pain relief rate, improvement rate of sleep quality and diet improvement rate in the experimental group were higher than those in the control group (P<0.05). The incidence of adverse reactions in the experimental group was slightly lower than that in the control group, but the difference was not statistically significant (P>0.05). Followed up for 1 years, 28 patients in the experimental group survived, and 22 cases in the control group survived. The survival rate in the experimental group was higher than that in the control group (P<0.05). Conclusion: The curative effect of Addie injection combined with Gefitinib Tablets is better than sim- ple application of Gefitinib Tablets in the treatment of EGFR positive advanced NSCLC, can improve sleep quality and diet condition, re- lieve pain, better safety, so as to improve the prognosis of patients, it is worthy of clinical promotion. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
